BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2953414)

  • 1. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
    Long HJ; Powis G; Schutt AJ; Moertel CG
    Cancer Treat Rep; 1987 Jun; 71(6):593-8. PubMed ID: 2953414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
    Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
    Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
    Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
    Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.
    Dorr FA; Von Hoff DD; Kuhn JG; Schwartz R; Kisner DL
    Cancer Res; 1986 May; 46(5):2562-5. PubMed ID: 2938729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of menogaril in patients with advanced cancer.
    Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
    J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
    Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
    Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of intravenous menogaril in patients with advanced breast cancer.
    Sessa C; Gundersen S; ten Bokkel Huinink W; Renard J; Cavalli F
    J Natl Cancer Inst; 1988 Sep; 80(13):1066-9. PubMed ID: 2970554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and disposition of menogaril (NSC 269148) in the rabbit.
    Dodion P; Egorin MJ; Engisch KL; Bachur NR
    Cancer Res; 1985 Nov; 45(11 Pt 1):5352-7. PubMed ID: 2932217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
    Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
    Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of oral menogaril administered on three consecutive days.
    Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Joggi J; Kenis Y
    Acta Oncol; 1988; 27(5):517-20. PubMed ID: 2974291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of i.v. menogaril in patients with malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group Study.
    McCulloch PB; Eisenhauer EA; Shibata HR; Young VP
    Cancer Treat Rep; 1987; 71(7-8):771-2. PubMed ID: 2955887
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.
    Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Piccart M; Tueni E; Joggi J; Kenis Y
    Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1019-26. PubMed ID: 2970391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.
    Zanette ML; Tirelli U; Sorio R; Zadro D; Figoli F; Monfardini S; D'Incalci M
    Cancer Chemother Pharmacol; 1987; 20(1):67-70. PubMed ID: 2957106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of intravenous menogaril administered intermittently.
    Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
    J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of menogaril in advanced malignant melanoma. An EORTC trial.
    Gundersen S; Monfardini S; Renard G; Van Glabbeke M; Pinedo H
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1707-8. PubMed ID: 2962875
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure.
    Buckner JC; Edmonson JH; Ingle JN; Schaid DJ
    Am J Clin Oncol; 1989 Oct; 12(5):384-6. PubMed ID: 2529759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of menogaril in advanced colorectal cancer.
    Holdener EE; ten Bokkel Huinink WW; Decoster G; Ludwig C; Renard G; Pinedo HM
    Invest New Drugs; 1988 Sep; 6(3):227-30. PubMed ID: 2973448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of menogaril in patients with advanced colorectal carcinoma: an Illinois Cancer Council trial.
    Locker GY; Kilton L; Hoeltgen T; Knop RH; Benson AB; Chernicoff D; Barrett J; Blough R; Johnson C
    Cancer Treat Rep; 1987 Sep; 71(9):871-2. PubMed ID: 2957053
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of intravenous menogaril in advanced ovarian carcinoma. EORTC Early Clinical Trials Group.
    Sessa C; Kaye SB; Renard J; ten Bokkel Huinink W; Cavalli F
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):751-2. PubMed ID: 2523809
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I study of weekly intravenous administration of menogaril to adults with solid tumors.
    Stewart DJ; Maroun JA; Verma S; Perrault D; Earhart RH
    Am J Clin Oncol; 1989 Dec; 12(6):511-8. PubMed ID: 2531540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.